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Targeting CD8+ T cells to recurrent tumor-specific mutations can profoundly contribute
to cancer treatment. Some of these mutations are potential tumor antigens although
they can be displayed by non-spliced epitopes only in a few patients, because of the low
affinity of the mutated non-spliced peptides for the predominant HLA class I alleles. Here,
we describe a pipeline that uses the large sequence variety of proteasome-generated
spliced peptides and identifies spliced epitope candidates, which carry the mutations
and bind the predominant HLA-I alleles with high affinity. They could be used in adoptive
T cell therapy and other anti-cancer immunotherapies for large cohorts of cancer
patients. As a proof of principle, the application of this pipeline led to the identification
of a KRAS G12V mutation-carrying spliced epitope candidate, which is produced by
proteasomes, transported by TAPs and efficiently presented by the most prevalent HLA
class I molecules, HLA-A∗02:01 complexes.
Keywords: proteasome, peptide splicing, adoptive T cell therapy targets, antigen presentation, cancer epitopes,
KRAS, tumor immunology
INTRODUCTION
Activating CD8+ T cells to recurrent tumor-specific mutations is one of a number of cutting-
edge strategies to treat cancer. It can be achieved by immunotherapy approaches such as adoptive
T cell therapy (ATT), peptide vaccination and dendritic cell (DC) vaccination. Neoepitopes that
carry cancer recurrent mutations and efficiently bind common Human Leukocyte Antigen class I
(HLA-I) variants are ideal targets for tumor immunology vaccination of large cohorts of patients.
Mishto et al. Pipeline Identifying Spliced Neoepitope Candidates
Peptide epitopes are generally produced by proteasomes,
which are the final effectors of the ubiquitin-proteasome
system (1). Epitope production is the first step of the antigen
processing and presentation (APP) pathway, which accounts for
the epitope translocating into the endoplasmic reticulum (ER)
lumen throughmediation by transporters associated with antigen
processing (TAPs), binding to the peptide loading complex,
trimming by exopeptidases, binding to the HLA-I complex,
and transport to the cell surface for recognition by cytotoxic
T lymphocytes (CTLs) (2).
There are several proteasome isoforms that can be involved
in APP. The most active proteasome isoform is a large (26S)
protease consisting of a 20S proteasome core coupled to one
or two 19S regulatory complexes. The 19S subunit contains the
ubiquitin recognition and removal system as well as an unfolding
activity, the 20S form is the actual protease. The 20S proteasome
is constituted of four rings; two α rings at the apexes; and two β
rings forming the central chamber. Each ring has seven distinct
subunits. Each β ring carries three catalytic (i.e., β1, β2, and β5)
subunits, which have distinct preferences for peptide sequence
motifs (1). Human cells can express different isoforms of
catalytic subunits, which are incorporated in distinct proteasome
isoforms. Standard proteasomes (s-proteasomes) contain β1, β2,
and β5 subunits. Immunoproteasomes (i-proteasomes) contain
β1i, β2i, and β5i subunits and are constitutively present
in immune cells, such as mature DCs, as well as in cells
exposed to an inflammatory milieu (3). Tumors express various
intermediate-type proteasome isoforms, in which standard- and
immuno-subunits are assembled in one proteasome complex
(4, 5). 20S proteasome is also functional alone in cells or coupled
to other regulatory subunits such as PA28 αβ (3, 6, 7).
Proteasomes can break proteins and release the peptide
fragments or re-ligate them, thereby forming “spliced peptides,”
which have sequences that do not recapitulate the linear sequence
of the parental protein (3, 8, 9). Spliced peptides may represent a
sizeable portion of the peptide pool bound to HLA-I molecules—
i.e., the HLA-I immunopeptidome—of tumor and non-tumor
human cell lines (10–12). This hypothesis is currently a matter of
debate since different analytical approaches obtained discordant
results (10–16). According to our previous analysis, however,
several antigens displayed by HLA-I immunopeptidomes are
represented only by spliced peptides. The antigens represented
by spliced peptides seem to be longer, more hydrophobic and
more basic than those represented by non-spliced peptides.
Antigens that are represented by both spliced and non-spliced
peptides show antigenic hot spots, i.e., antigenic areas fromwhich
both spliced and non-spliced peptides derive (12). HLA-I-bound
spliced peptides are generally less abundant than non-spliced
peptides (10–12, 17). Proteasome-generated spliced epitopes can
trigger specific CTL responses ex vivo/in vivo against tumor- and
type 1 diabetes-associated antigens (17, 18) as well as pathogens
(19). ATT targeting a spliced epitope successfully treated a
melanoma patient (20, 21).
Proteasome-catalyzed peptide splicing (PCPS; see Figure 1A)
can occur by combining two non-contiguous sequences of the
same molecule (cis PCPS) or of two distinct molecules (trans
PCPS). The latter seems to be efficiently catalyzed in vitro by
purified proteasomes (22–24) and may constitute a large portion
of the HLA-I associated spliced immunopeptidomes (11).
Although the role of spliced peptides in central tolerance still
has to be investigated, the theoretically large sequence variability
of spliced peptides makes them attractive for anti-cancer
immunotherapy (25). Indeed, some of the most recurrent driver
mutations in tumors often cannot be efficiently represented
by canonical non-spliced peptides bound to the predominant
HLA-I variants because of antigen sequence restrictions. On
the contrary, they might be represented on the cell surface by
tumor-specific spliced epitopes. Therefore, the identification of
tumor antigen-specific spliced epitopes might represent a unique
opportunity to treat a large cohort of patients.
We here present a pipeline combining in silico and in vitro
approaches. It successfully identifies tumor-specific spliced and
non-spliced epitope candidates, which can be further validated
as targets for anti-cancer immunotherapies, as illustrated by the
HLA-A∗02:01+ KRAS G12V+ spliced epitope candidate here
described (Figure 1B).
MATERIALS AND METHODS
Antigen Selection and Spliced Epitope
Candidate Identification
To rank antigens that are over-represented in HLA-I
immunopeptidomes by spliced and non-spliced peptides
according to their protein characteristics, we generated a
simple model based on the following characteristics: length,
hydrophobicity index, isoelectric point, and instability index.
We first calculated these characteristics for all proteins in
the Uniprot Reference human proteome database. Next, we
analyzed the previously published HLA-I immunopeptidomes of
GR-LCL, HCC1143 and HCT116 cell lines (12). All identified
spliced and non-spliced peptides were mapped to their antigen(s)
of origin, thereby determining a set of represented antigens.
Among those antigens not represented in the MS-detected HLA-
I immunopeptidomes, there are likely many antigens that would
be represented if we considered larger HLA-I immunopeptidome
datasets. For this reason, we compared the characteristics of the
represented antigens to the characteristics of all proteins (control
set). The aim was to determine a combination of the four selected
protein characteristics that has the largest difference between the
represented antigen set and the control set.
We define the feature sum (f ) as: f =
∑
pi ci, where c is
the vector of the four selected features (length, hydrophobicity
index, isoelectric point and instability index) and p is the vector
of factors ranging from −1 to 1. A factor of −1 would favor
presentation, while a factor of 1 would disfavor presentation.
We use Bayesian inference in a Markov Chain Monte Carlo
scheme to determine the factors that result in a distribution of
f for represented antigens (F1), which is most different to the
distribution of f for control proteins (F0). The difference between
the densities Fdiff = F1-F0 indicates which f is favoring (positive
values) or disfavoring (negative values) protein representation.
Next, we calculated Fdiff (f) for a set of candidate antigens
(BRAF, KRAS, HRAS, NRAS, TP53, CDK4, IDH1, TYR) using
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FIGURE 1 | Proteasome-catalyzed peptide splicing and the in silico/in vitro pipeline to identify tumor-specific spliced epitope candidates. (A) Proteasome-generated
spliced peptides can be formed by: (i) cis PCPS, when the two splice-reactants derive from the same polypeptide molecule, the ligation can occur in normal order, i.e.,
following the orientation from N- to C-terminus of the parental protein (normal cis PCPS), or in reverse order (reverse cis PCPS); (ii) trans PCPS, when the two
splice-reactants originate from two distinct protein molecules or two distinct proteins. PSP-P1 and PSP-P1’ are the C-terminal residue of the N-terminal
splice-reactant and the N-terminal residue of the C-terminal splice-reactant, respectively. The splice-reactants are separated by the intervening sequence. (B)
Representation of the steps of the in silico – in vitro pipeline proposed here. Through its application, we identified an HLA-A*02:01+ KRAS G12V+ spliced epitope
candidate (center gray frame).
the Kolmogorov-Smirnov distance. To do so, we sampled
(N = 1,000) from the posterior distribution of factors resulting
in distributions of Fdiff for each candidate antigen. Antigens
with the highest Fdiff have characteristics that lead to more likely
representation of those antigens in HLA-I immunopeptidomes.
Peptide Synthesis and Proteasome
Purification
All peptides were synthesized using Fmoc solid phase chemistry
(Supplementary Table 2). 20S proteasome was purified from
peripheral blood as follows: (i) 10ml peripheral blood was
homogenized, lysed and centrifuged; (ii) the supernatant was
fractionated by ammonium sulfate precipitation (35% and then
75%); (iii) the latter pellet was fractioned by chromatography
on DEAE-Sephacel; (iv) the selected fractions were separated
by 10–40% sucrose gradient and followed by (v) anion
exchange chromatography on Mono Q in an Akta-FPLC
system; (vi) the selected fractions (2–4mL) were further
purified by DEAE-Affi-gel-blue chromatography. In each of
the (ii–vi) steps, the fractions were monitored by degradation
assays of standard short fluorogenic substrate Suc-LLVY-AMC.
Proteasome concentration was measured by Bradford staining
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and verified by Coomassie staining of an SDS-Page gel, as shown
elsewhere (26). The purity of the preparation using this protocol
has been previously shown (27).
In vitro Digestions and MS Measurements
Synthetic polypeptides (40µM) were digested by 3 µg 20S
proteasomes in 100 µl TEAD buffer for different time points (0–
20 h) at 37◦C, as previously described (27). We performed three
independent experiments, each of them measured either 3 times
(for the 0–4 h kinetics) or 2 times (for 20 h digestions) by mass
spectrometry (MS).
The identification of target peptide products was carried out
by targeted MS using a mass to charge ratio (m/z) inclusion
list. The inclusion list was comprised of all theoretically possible
8–12mer spliced and non-spliced peptide products derived
from KRAS2−35 G12V synthetic polypeptide substrate, which
carried the G12V mutation and were predicted to bind HLA-
A∗02:01 complex with IC50 ≤ 100 nM (see below). The same
principle was applied for the peptide products derived from
the wild type KRAS2−35 G12 synthetic polypeptide substrate
(Supplementary Table 1). To this end, 20 h in vitro digestions
with 20S proteasomes were measured by Fusion Lumos Mass
Spectrometer (Thermo Fisher Scientific). Prior to measurement,
the samples were diluted with the loading buffer (2% acetonitrile,
0.05% Trifluoroacetic acid) containing human insulin (Sigma-
Aldrich) to a final substrate concentration of 25µM and insulin
concentration of 2µM. Insulin was used as a coating polymer
to prevent binding of peptides to the glass vials used for
measurements and to improve reproducibility between technical
replicates. Eightµl of those dilutions (corresponding to 200 pmol
of substrate initially present in the sample) were injected. Samples
were loaded and separated by a nanoflow HPLC (RSLC Ultimate
3000) on an Easy-spray C18 nano column (30 cm length,
75µm internal diameter) coupled on-line to a nano-electrospray
ionization Fusion Lumos mass spectrometer (Thermo Fisher
Scientific). Peptides were eluted with a linear gradient of 5–55%
buffer B (80% ACN, 0.1% formic acid) over 88min at 50◦C at
a flow rate of 300 nl/min. The instrument was programmed
within Xcalibur 3.1.66.10 to acquireMS data in a Data Dependent
Acquisition mode using Top 20 precursor ions. We acquired
one full-scan MS spectrum at a resolution of 120,000 with an
automatic gain control (AGC) target value of 1,000,000 ions and
a scan range of 300–1,600 m/z with maximum injection time
set to 50ms and intensity threshold set to 50,000. The MS/MS
fragmentation was conducted using HCD collision energy (35%)
with an orbitrap resolution of 30,000 at 1.4 m/z isolation window
with Fixed First Mass set to 105 m/z. The AGC target value was
set up at 100,000 with a maximum injection time of 128ms. A
dynamic exclusion of 30 s and 1–7 included charged states were
defined within this method.
In vitro proteasome-mediated digestion kinetics (0–4 h) and
the 20 h digestions were measured by LC-MS/MS as follows:
Prior to measurement, samples were diluted with the loading
buffer and insulin as described above. Eight µl (i.e., 200 pmol
substrate) of those dilutions were loaded. Samples were loaded
and separated by a nanoflow HPLC (RSLC Ultimate 3000)
on an Easy-spray C18 nano column (30 cm length, 75µm
internal diameter; Dr. Maisch) coupled on-line to a nano-
electrospray ionization Q Exactive Hybrid-Quadrupol-Orbitrap
mass spectrometer (Thermo Fisher Scientific). Peptides were
eluted with a linear gradient of 5–55% buffer B (80% ACN, 0.1%
formic acid) over 88min at 50◦C at a flow rate of 300 nl/min.
The instrument was programmed within Xcalibur 3.1.66.10 to
acquire MS data in a Data Dependent Acquisition mode using
Top 20 precursor ions. We acquired one full-scan MS spectrum
at a resolution of 70,000 with an automatic gain control (AGC)
target value of 1,000,000 ions and a scan range of 350∼1,600
m/z. The MS/MS fragmentation was conducted using HCD
collision energy (30%) with an Orbitrap resolution of 35,000
at 2 m/z isolation window with Fixed First Mass set to 110
m/z. The AGC target value was set up at 100,000 with a
maximum injection time of 128ms. For Data Dependent Scans
the minimum AGC target value and the Intensity threshold
were set to 2,600–20,000 accordingly. A dynamic exclusion
of 25 s and 1–6 included charged states were defined within
this method.
Spliced and Non-spliced Peptide
Identification and Quantification As Well as
Computation of SCS-P1 and PSP-P1
Peptides were identified using the Mascot version 2.6.1
(Matrix Science) search engine. Mass spectra were searched
against a customized database that includes all theoretically
possible spliced and non-spliced peptides (28). M oxidation,
N-terminal acetylation and NQ deamidation were set as variable
modification. For the peptide identification in the Orbitrap
Q Exactive measurements, we set as mass tolerances for MS
and MS/MS 6 ppm and 20 ppm, respectively. For the peptide
identification in the Fusion Lumos measurements, we set as mass
tolerances for MS and MS/MS 5 ppm and 0.03 Da, respectively.
Peptide hits were filtered using an ion score cut-off of 20, a
q-value cut off of 0.05 and a delta score between two spliced
peptide hits or between a top scoring spliced peptide and a lower
scoring non-spliced peptide of 30% (12). Mascot Distiller’s label-
free quantification toolbox was used to automatically extract
MS ion peak areas of all identified peptides for all five time
points (0–4 h) and all three technical replicates simultaneously.
Biological replicates were processed separately. The resulting
peptide kinetics were filtered for peptide synthesis artifacts and
non-reproducible peptide kinetics between technical replicates.
Furthermore, peptides that showed unrealistic generation kinetic
behavior (such as alternating MS ion peak areas between
consecutive time points) were removed. In the final analysis,
only peptides that were detected and quantified in two biological
replicates were considered.
KRAS5−6/8−14 G12V and KRAS5−14 G12V generation
kinetics were manually quantified by extraction of an
ion chromatogram (XIC) corresponding to the peptides
monoisotopic peaks, using instrument precursor tolerance
and retention time information (from the identified peptides
in the 20 h digestions) via Mascot Distiller, followed by
determination of the area under the peak at each time point in the
kinetics series.
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Absolute peptide quantification was carried out through
the application of the method QPuB on detected MS ion
peak areas for each peptide product, as described elsewhere
(see Data availability section). In the specific case of the two
epitope candidates KRAS5−6/8−14 G12V and KRAS5−14 G12V,
we computed their amount using a titration curve of the
cognate synthetic peptides since their amount was too low
to be estimated with high confidence using QPuB. Synthetic
peptide concentration for titration ranged from 0 to 10 pmol
injected. Each titration sample wasmeasured twice and right after
measuring in vitro digestion samples.
SCS-P1 (site specific cleavage strength after amino acid residue
P1) and PSP-P1 (frequency of peptide splicing catalyzed using
the C-terminus of the N-terminal splice-reactant as splicing
site) were calculated based on the absolute amount of each
product (resulting from QPuB) identified in the proteasome-
catalyzed digestions (23). Briefly, for each time point and each
amino acid in the substrate, the sum over all product (non-
spliced and spliced peptides) amount that have the corresponding
substrate amino acid at their C-terminus has been computed and
normalized, so that they add up to 100%, resulting in SCS-P1.
For each time point and each amino acid in the substrate, the
sum over all spliced peptide amount that have the corresponding
substrate amino acid at their C-terminus of the N-terminal
splice-reactant was computed and normalized, so that they add
up to 100%, resulting in PSP-P1.
TAP Assay
The transport efficiency of target peptides
(Supplementary Table 2) into the ER lumen mediated by
TAPs was carried out as previously described (29) although
some modifications were introduced. These include the use
of a fluorescent peptide tracer and the use of microsomes
rather than Streptolysin O permeabilized cells. Briefly, peptides
were dissolved in DMSO and different concentrations were
distributed in a final volume of 10 µl DMSO. At the same
time, a mixture of 10mM ATP, 100mM Tris-HCl pH7.5 and
5mM MgCl2 and fluorescent tracer peptide was prepared. 60
µl of this mixture was added to the 10 µl competing peptide
mixture to a final volume of 70 µl. This was prewarmed
to 37◦C and 30 µl of pre-warmed microsomes were added.
Microsomes were derived from LCL721 cells, as previously
described (29).
The mixture was incubated for 20min at 37◦C followed
by cell lysis with lysis mixture (0.5% TX100, 5mM MgCl2
in 100mM Tris-HCl pH7.5) at 4◦C. After at least 30min
incubation at 4◦C, DNA was pelleted and the supernatant
transferred to a new vial including ConA-beads. After at
least 30min incubation on ice, cells were washed four times
with lysis mixture and the last time with 100mM Tris-HCl
pH7.5 before transfer to 96 wells plates (Corning) followed
by fluorescence measurements in a plate reader. To detect
background signals, a sample without competing peptide and
ATP was included and fully performed as described above. This
signal was subtracted from the detected signal. The curves were
normalized to the highest value set at 100% and EC50 values
were calculated.
HLA-I–Peptide Binding Affinity Prediction
and Measurement
The binding affinity between theoretical spliced and non-
spliced peptides and HLA-A∗02:01 was predicted using the
NetMHCPan 3.0 algorithm (30). We restricted the prediction to
8–12 mer peptides and imposed an IC50 cut-off of 100 nM. The
binding affinity between the synthetic peptides andHLA-A∗02:01
complexes was measured using purified HLA-I molecules, as
described elsewhere (10).
HLA-I-Peptide Crystal Structure and
Analysis
The ectodomains of HLA-A∗02:01 (residues 21–274) and human
β2-microglobulin (hβ2m) (residues 1–99) were expressed in
Escherichia coli BL21 DE3 cells as inclusion bodies after
4 h induction with 1mm isopropyl 1-thio-d-galactopyranoside
(IPTG) at A600 of 0.6. Cells were harvested by centrifugation
(5,000 × g for 20min), resuspended in lysis buffer (100mM
Tris-HCl, pH7.0, 5mM EDTA, 5mM DTT, 0.5mM PMSF),
and broken through a microfluidizer (Microfluidics). Inclusion
bodies were collected from cell lysate (50,000 × g for
30min at 4◦C), washed 3 times in 100mM Tris-HCl, pH7.0,
5mM EDTA, 5mM DTT, 2M urea, 2% (w/v) Triton X-
100 plus 1 time in 100mM Tris-HCl, pH7.0, 5mM EDTA,
2mM DTT), and finally dissolved in 50mM Tris-HCl, pH7.0,
5mM EDTA, 2mM DTT, 6M guanidine HCl) for the
following refolding.
Refolding was performed in a 100ml system. Briefly,
1.2mg of hβ2m was loaded dropwise into refolding
buffer (0.1M Tris-HCl, pH8.0, 2mM EDTA, 400mM
l-arginine, 5mM oxidized glutathione, 5mM reduced
glutathione) and stirred for 1 h at 4◦C. Then, 6mg of
HLA-A∗02:01 mixed with 1.2mg of individual peptide
(Supplementary Table 2) was added dropwise into the
refolding system and stirred at 4◦C for up to 72 h. The
refolding system was concentrated to 0.5mL for size exclusion
chromatography using a Superdex S200 Increase 10/300
GL column in 20mM Tris-HCl pH7.5, 150mM NaCl.
Fractions containing refolded HLA-A∗02:01-β2m-peptide
complexes were pooled and concentrated to 5–10 mg/ml for
subsequent crystallization.
Thick plate-like or 3-dimensional crystals of HLA-A∗02:01-
β2m-peptide complexes were obtained by setting drop vapor
diffusion at 1:1–1.5 ratio with 30% PEG 4000, 0.1M Tris-HCl,
pH8.5, 0.2M lithium sulfate at room temperature after 3 days.
The crystals were flash frozen in crystallization solution plus
glycerol (25% v/v) using liquid nitrogen.
Diffraction data for HLA-A∗02:01-β2m-peptides were
collected remotely at beam line 9.2 at the Stanford Synchrotron
Radiation Light source and processed to 1.40–1.55 Å resolution,
using HKL2000. Phases were obtained by molecular replacement
with Phaser MR in ccp4 using the protein coordinates from a
former HLA-A∗02:01-β2m-peptide structure (Protein Data Bank
code 5ENW) (31). The model was built with COOT (32) and
refined with REFMAC5 (33). Data collection and refinement
statistics are shown in Supplementary Table 3.
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Statistical Analysis
If not stated otherwise, all statistical tests have been done in
R and differences in distributions have been tested using the
Kolmogorov-Smirnov test.
Dataset and Software Availability
A summary of the RAW files of the LC-MS/MS measurements
of the in vitro digestions accessible via repository is reported
in the following Mendeley dataset: http://doi.org/10.17632/
63rj3xczmb.1.
The mass spectrometry proteomics data have been deposited
to the ProteomeXchange Consortium via the PRIDE (34) partner
repository with the dataset identifier PXD015580.
The HLA-I immunopeptidome elution MS files
used in the first step of the pipeline are available
at the PRIDE repository with the dataset identifier
PXD000394 (files: 20120321_EXQ1_MiBa_SA_HCC1143_1.raw,
20120321_EXQ1_MiBa_SA_HCC1143_2.raw, 20120322_EXQ1
_MiBa_SA_HCC1143_1_A.raw, 20120515_EXQ3_MiBa_SA_
HCT116_mHLA-1.raw, 20120515_EXQ3_MiBa_SA_HCT116_
mHLA-2.raw, 20120617_EXQ0_MiBa_SA_HCT116_1_mHLA_
2hr.raw, 20120617_EXQ0_MiBa_SA_HCT116_2_mHLA_2hr.
raw) and at the Datadryad.org archive (doi: 10.5061/dryad.r984n)
and were generated by Bassani et al. (35) andMommen et al. (36).
QPuB software is available at GitHub (https://github.com/
QuantSysBio/QPuB).
RESULTS
Prioritization of KRAS as Antigen
Over-represented on Cell Surface
Antigens represented by spliced peptides in HLA-I
immunopeptidomes tend to be preferentially long, hydrophobic
and basic, thereby suggesting that the chemical and physical
characteristics of antigens can impinge upon spliced peptide
generation and presentation (12, 24). To select suitable antigens
from which a spliced epitope candidate might be derived, we
first investigated which combination of protein features may
result in more likely potential over-representation in HLA-I
immunopeptidomes by spliced and non-spliced peptides.
Accordingly, we used a previously published HLA-I spliced
and non-spliced immunopeptidome database (12), which
includes 13,666 unique non-spliced and 1,318 unique spliced
peptides, as well as 7,328 represented antigens. With this
dataset, we developed a simple model based on protein
length, hydrophobicity, isoelectric point and instability index to
determine the possible over-representation of a given antigen by
spliced and non-spliced peptides in HLA-I immunopeptidomes.
These characteristics were previously described to influence the
probability of observing peptides of a protein being presented
in HLA-I immunopeptidomes determined by antigen gene
expression level and antigen abundance as key determinants
for efficient presentation (12, 37). However, we here opted to
focus on protein intrinsic characteristics that are conserved
independently of cell types and cell status, to obtain a model for
antigen selection that can be generalized.
Combining these four selected protein characteristics yielded
a distribution of known represented antigens, which can be
compared to the feature distribution of all proteins (Figure 2A).
Proteins with feature values that show a higher density for
represented antigens compared to all proteins are more likely
to be favored for antigen presentation than those proteins with
feature values that show a lower density for represented antigens
compared to all proteins (Figure 2A). We therefore aimed to find
a combination of features that maximizes the difference between
the two distributions. We defined a model calculating a feature
sum
∑
pi ci, where pi are factors ranging from −1 (favoring
representation) to 1 (disfavoring representation) and ci are the
protein characteristic values.
Using Bayesian inference, we estimated the factors that
provide the largest distance between the resulting feature sum
distributions for represented antigens compared to all proteins.
We found that protein length favors representation. On the
contrary, very hydrophobic or instable proteins are disfavored
during representation. The isoelectric point appeared to have
minor influence (Figure 2B).
As proof-of-principle, we focused our analysis on a series
of major tumor antigens - BRAF, KRAS, HRAS, NRAS, TP53,
CDK4, IDH1, TYR - which all carry recurrent oncogenic
mutations. We calculated the feature sums for those eight
antigens and determined corresponding density differences for
each of those feature sums, which allowed us to rank the
candidate antigens (Figure 2C). Among them, HRAS and KRAS
are the two antigens that are most likely over-represented
in HLA-I immunopeptidomes as compared to the whole
proteome (Figure 2C).
Prioritization of KRAS G12V neoantigen as
Source of Potentially Antigenic
HLA-A∗02:01-Bound Tumor-specific
Spliced Peptides
HRAS and KRAS are two GTPases that function as molecular
switches in regulatory pathways responsible for proliferation and
survival. In particular, KRAS is frequently mutated in cancers
with an average of 22% cancers carrying a KRAS mutation,
a frequency that rises to 33–61% in colorectal cancer and
pancreatic adenocarcinoma (38). The mutations often occur in
the KRAS G12 and G13 residues, which impairs the KRAS
GTPase activity and renders the mutants persistently in the
GTP-bound active form, thereby promoting tumorigenesis and
tumor malignancy (39). KRAS G12/13 is a driver in tumors
and in combination with its high frequency in cancers makes
KRAS an ideal target for immunotherapies. For example, ATT
using multiple T cell Receptors (TCRs), which recognize HLA-
A∗02:01+ spliced epitopes carrying KRAS mutations, could treat
around 30% of pancreatic adenocarcinoma patients and a large
portion of colorectal carcinoma patients. The efficacy of ATT
has been demonstrated in a xenograft mouse model (40) and
a metastatic colorectal cancer patient (41) by targeting non-
spliced epitopes carrying KRAS G12D mutations and presented
by HLA-A∗11:01 or -C∗08:02 molecules, respectively.
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FIGURE 2 | Prioritization of KRAS G12V as source of potentially antigenic HLA-A*02:01-bound spliced peptides. (A) Illustration of a model to select antigens with
features more likely to be over-represented in HLA-I immunopeptidomes. Protein length, hydrophobicity, isoelectric point and instability are used to calculate a protein
feature sum for all represented antigens. The resulting distribution (orange line) is compared to the feature sum distribution based on all human proteins (gray line). The
difference between these two distributions (red line) indicates which features favor and disfavor the representation of antigens in HLA-I immunopeptidomes. (B)
Marginal posterior distributions of the estimated factors that maximize the difference between feature sum distribution of represented antigens vs. all proteins. (C)
Ranking of selected tumor-associated antigens BRAF, KRAS, HRAS, NRAS, TP53, CDK4, IDH1, TYR as antigens with features over-represented in HLA-I
immunopeptidomes. (D) Progressive reduction of the theoretical number of spliced and non-spliced epitope candidates, thereby narrowing down to those carrying
KRAS G12V/D/R or G13D mutations (in silico derived from the KRAS2−35 sequence) and predicted to bind HLA-A*02:01 with IC50 ≤ 100 nM.
All these features define KRAS as an attractive tumor antigen
to be further investigated using our pipeline. We investigated in
silico the sequence surrounding residues 12 and 13 of KRAS wild
type, G12V/D/R and G13D antigens. All spliced and non-spliced
peptides that could be theoretically generated were computed.
From this list, we removed all peptide candidates not carrying
the target mutations, as well as those candidates shorter than 8
residues or longer than 12 residues, which is the length range
most often observed in HLA-I immunopeptidomes (Figure 2D).
Since the HLA-A∗02:01 allele is the predominant allele in
Caucasian populations, we predicted the binding affinity of this
HLA-I variant to the remaining peptides using the NetMHCPan
3.0 algorithm (30). Finally, we filtered out all peptides that
were predicted to bind with IC50 > 100 nM. None of the non-
spliced epitope candidates passed this step, whilst 54 spliced
epitope candidates had the required features. Among them, 47
can theoretically carry the KRAS G12V mutation (Figure 2D).
Identification of KRAS G12V+ Spliced
Epitope Candidates Generated by
Proteasomes
The majority of the HLA-I-restricted epitopes are produced
by proteasomes. Their production can be verified through in
vitro digestion of synthetic polypeptides by 20S proteasomes,
as measured by MS. Because of the high frequency of putative
HLA-A∗02:01+ spliced epitope candidates carrying the KRAS
G12V mutation (KRAS G12V+), we focused on this mutation
and digested the synthetic KRAS2−35 wild type and G12V
polypeptides with 20S standard proteasomes for 20 h. The
digestions were measured by targeted MS, which used a m/z
inclusion list of target spliced epitope candidates identified
in the previous pipeline step (Supplementary Table 1), and
confirmed that one spliced epitope candidate, KRAS5−6/8−14
G12V [KL][VVGAVGV], is generated by proteasomes under
these conditions (Figure 3). This spliced peptide could be
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FIGURE 3 | MS/MS spectra of the KRAS5−6/8−14 G12V spliced epitope candidate. MS/MS spectrum of the peptide KRAS5−6/8−14 G12V [KL][VVGAVGV] identified in
the in vitro digestion of the synthetic polypeptide KRAS2−35 G12V and the MS/MS spectrum of the cognate synthetic peptide (left panels). The peptide sequence is
shown with the corresponding b-, a- and y-ions identified. The G12V mutation is depicted in bold. In the spectra, assigned peaks for b-, a-, and y-ions are reported in
color. Ion neutral loss of ammonia is symbolized by *. Red marked peaks are assigned in both in vitro digestion detected MS/MS spectrum and synthetic peptide
MS/MS spectrum, whereas blue marked peaks are assigned only in one of the two spectra. The extracted ion chromatogram for the peptide identified in the in vitro
digestion and the synthetic counterpart is plotted and indicates matching retention times for both peptides (right panels).
generated by the removal of one of the three V residues in the
KRAS sequence, i.e., it could be reported as KRAS5−6/8−14 G12V,
KRAS5−7/9−14 G12V, or KRAS5−8/10−14 G12V. We will refer to
it as KRAS5−6/8−14 G12V for the sake of simplicity.
Notably, this spliced peptide is not present in the reaction at
t = 0 and the 20 h reaction containing the synthetic polypeptide
substrate in absence of proteasomes (data not shown). The
cognate spliced peptide KRAS5−6/8−14 G12 [KL][VVGAGGV] is
not produced by 20S proteasomes whilst processing the synthetic
wild type KRAS2−35 polypeptide.
In the KRAS2−35 G12V polypeptide digestion, we also
identified the non-spliced epitope candidate KRAS5−14 G12V
[KLVVVGAVGV] (Supplementary Figure 1). The spontaneous
response of peripheral blood mononuclear cells (PBMCs) of
pancreatic adenocarcinoma patients against this latter epitope
candidate was previously described (42). Although this peptide
was filtered out in the early steps of our pipeline because it has
a predicted HLA-A∗02:01 binding affinity IC50 > 100 nM, we
compared this epitope candidate to the KRAS5−6/8−14 G12V
spliced epitope candidate in the next validation steps.
Spliced Peptide and KRAS5–6/8–14 G12V
Spliced Epitope Candidate Production
Kinetics by Proteasomes
To be a robust epitope candidate, a peptide should be
produced in vitro by proteasomes in a detectable amount
and with consistent kinetics. Correspondence between in vitro
experiments carried out with purified 20S proteasomes and
in cellulo and in vivo experiments has been demonstrated in
various studies investigating both viral and tumor epitopes
(4, 5, 9, 17, 19, 21, 43–50). Therefore, we performed digestion
kinetics (0–4 h) of the synthetic KRAS2−35 wild type and G12V
polypeptides with 20S standard proteasomes. The samples were
measured by MS to identify all digestion products (via MS/MS).
Quantification of peptides was performed using QPuB, a method
that uses detected MS ion peak areas to estimate the absolute
amount of each spliced and non-spliced peptide products (see
Data Availability section), and by comparison with synthetic
peptide titration for the two epitope candidates.
In the synthetic KRAS2−35 G12V polypeptide digestion, we
identified and successfully quantified 131 peptide products.
65.6% were non-spliced, 31.3% cis spliced and 3.1% trans spliced
peptides (Figure 4A). The length distribution of the non-spliced,
cis spliced and trans spliced peptides did not significantly differ
and its median was 10 amino acid residues (Figure 4B). N-
and C-terminal splice-reactants had a median length of 7 and
3 amino acid residues, respectively (Figure 4C). The intervening
sequences of cis spliced peptides had a median length of 5 amino
acid residues (Figure 4C). From the quantitative point of view,
cis and trans spliced peptides represent proximately 17.0 and
0.1% of the peptide abundance, respectively (Figure 4D). On
average, a trans spliced peptide is less abundant than a cis spliced
peptide, which is less abundant than an average non-spliced
peptide (Figure 4E).
Through the application of QPuB to the synthetic KRAS2−35
wild type and G12V polypeptide digestions, we could also
compute how frequently proteasomes cleaved the substrate after
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FIGURE 4 | Spliced peptide characteristics and kinetics in KRAS2−35 G12V polypeptide degradation. (A–D) Results of the analysis of in vitro digestions of the
synthetic KRAS2−35 G12V polypeptide substrate by 20S proteasomes (two biological replicates each measured three times). Spliced and non-spliced peptide
products were identified by MS and quantified by applying QPuB. Only peptides identified in both biological replicates with reproducible kinetics have been analyzed.
(A) Number of non-spliced, cis spliced, and trans spliced peptides identified in the reactions. (B) Length distribution of non-spliced peptides, cis spliced and trans
spliced peptides. (C) Length distribution of N- and C-terminal splice-reactants of cis spliced peptides as well as of their intervening sequences. (D) Total amount of
spliced and non-spliced, as well as cis spliced and trans spliced peptides quantified by applying QPuB to in vitro kinetics. (E) Abundance of an average spliced and
non-spliced, as well as cis spliced or trans spliced, peptides in the in vitro kinetics over the digestion time. In (B,C), violin plots indicate the fragment length
distribution. Red lines indicate the median. When statistically significant, p-values are reported.
each of its individual residues (substrate cleavage strength, i.e.,
SCS-P1) or used each residue for the PCPS reaction (proteasome-
generated spliced peptide P1 positions, i.e., PSP-P1). From this
analysis we confirmed our previous hypothesis (23), whereby
proteasomes splice at sites at which the substrates are less
frequently cleaved at (and vice versa), as emerged by comparing
SCS-P1 and PSP-P1 (Figures 5A,B).
The quantitative analysis of the KRAS2−35 synthetic substrate
degradation (Figure 5C) also showed that the KRAS5−6/8−14
G12V spliced epitope candidate is produced in amounts smaller
than the average amount of spliced peptides (Figures 4E, 5D shall
be compared).
KRAS5–6/8–14 G12V Spliced Epitope
Candidate Is a TAP Substrate and
Efficiently Binds Hla-A∗02:01
The production of a peptide by proteasomes is not sufficient
alone to incur presentation on the cell surface. There are several
other steps in the APP pathway that can direct the peptide
fate, such as peptide transport into the ER lumen mediated
by TAPs and peptide binding to HLA-A∗02:01 complex. We
studied the KRAS5−6/8−14 G12V [KL][VVGAVGV] spliced
epitope candidate in comparison with the KRAS5−14 G12V
[KLVVVGAVGV] non-spliced epitope candidate. We also
extended the study to four control peptides. Two peptides -
peptide #1 YLVVVGAVGV and peptide #2 KLVVVAVGV -
shared a large portion of the KRAS5−6/8−14 G12V and KRAS5−14
G12V epitope candidate sequences (Figure 6A). The other two
control peptides are unrelated peptides predicted to bind to
the HLA-A∗02:01 complex (peptides #3 FLHEDLEKI and #4
FLHEDTEKI; see Supplementary Table 2).
To quantify the efficiency of peptide transport into the ER
lumen by TAP, we measured the competition between the target
peptides and a fluorescent reference peptide for TAP-dependent
translocation into free microsomes. The reference peptide has
an N-linked glycosylation consensus sequence and peptide
glycosylation is used to monitor entry into ER microsomes
and as an isolation handle (29). KRAS5−6/8−14 G12V epitope
candidate is efficiently transported by TAPs as the KRAS5−14
G12V non-spliced epitope candidate is. Peptide #1, which has
a K to Y substitution at position 1 as compared to KRAS5−14
G12V peptide, is transported by TAP as efficiently as the non-
spliced epitope candidate. In contrast, peptide #2, which has the
removal of residue G in position 6 as compared to KRAS5−14
G12V peptide and a G to V substitution at position 5 as compared
to KRAS5−6/8−14 G12V peptide, is not competing with the
reference peptide and thus ignored by TAP. This suggests a role
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FIGURE 5 | Substrate cleavage- and splicing-site preferences and generation kinetics of the KRAS5−6/8−14 G12V and KRAS5−14 G12V epitope candidates. (A)
Relative usage of the substrate sites for cleavage (SCS-P1), and splicing (PSP-P1) in the in vitro digestion kinetics of the synthetic KRAS2−35 G12V polypeptide
substrate by 20S proteasomes (two biological replicates each measured three times). Mean and SD of biological replicates (bars) are shown. (B) Scatter plot of
SCS-P1 and PSP-P1, which depicts the absence of direct correlation between splicing and cleavage frequencies. In (A,B) spliced and non-spliced peptide products
were identified by MS/MS in the in vitro digestion kinetics of synthetic polypeptide KRAS2−35 G12V with 20S proteasomes, and were quantified by applying QPuB
based on their MS ion peak area. SCS-P1 and PSP-P1 were computed using the average amount of all time points of each peptide product. (C,D) Abundance of the
synthetic polypeptide substrate KRAS2−35 (C) as well as the KRAS5−6/8−14 G12V and KRAS5−14 G12V epitope candidates (D) in the in vitro digestions with 20S
proteasomes (three biological replicates each measured 3–4 times). Spliced and non-spliced peptide products were identified by MS/MS and quantified based on
their MS ion peak area, using titration of synthetic peptides as reference.
FIGURE 6 | KRAS5−6/8−14 G12V epitope candidate is efficiently transported by TAPs and strongly binds HLA-A*02:01 complex. (A) Sequence comparison between
KRAS5−6/8−14 G12V [KL][VVGAVGV] and KRAS5−14 G12V [KLVVVGAVGV] epitope candidates as well as their modified versions (peptides #1 YLVVVGAVGV and #2
KLVVVAVGV). Common sequences among peptides are color-coded. (B) Transport efficiency into the ER lumen mediated by TAPs of KRAS5−6/8−14 G12V and
KRAS5−14 G12V epitope candidates, their modified versions (peptides #1 and #2) and two unrelated peptides (peptides #3 and #4; Supplementary Table 2). The
EC50 was computed using a competing peptide as reference. We here report the EC50 values obtained upon subtracting the peptide transport in absence of ATP. (C)
Predicted and measured binding affinities of the peptides to the HLA-A*02:01 complex. Binding affinity prediction was carried out with the NetMHCPan 3.0 algorithm.
In (B,C) mean and SD of biological replicates (bars) are shown.
of the residue G at the center of the peptides in TAP-mediated
transport. The other two control peptides are not substrates for
TAP (Figure 6B).
Once a peptide arrives in the ER lumen, its binding affinity to
the specific HLA-I molecule determines whether it will ultimately
be presented. Therefore, we measured the binding affinity of the
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same six peptides previously tested in the TAP assay and the
HLA-A∗02:01 complex in a cell-free system utilizing purified
HLA-I molecules. The KRAS5−6/8−14 G12V epitope candidate
was confirmed to efficiently bind the HLA-A∗02:01 complex, in
contrast to the KRAS5−14 G12V non-spliced epitope candidate,
which had a measured IC50 larger than 300 nM (and larger than
predicted). The measured and predicted IC50 of the control
peptides was quite similar and the peptides appear to be good
binders (Figure 6C).
Conformation of KRAS5–6/8–14 G12V and
KRAS5−14 G12V Epitope Candidates Within
HLA-A∗02:01 cleft
Once a peptide is bound to HLA-I complexes and presented
at the cell surface, it can be recognized by TCRs of CD8+ T
cells. The conformation of the peptide in the HLA-I groove
is paramount not only for HLA-I-peptide affinity and stability,
but also for the TCR-HLA-I-peptide interaction. To study
this aspect, we individually refolded and crystallized HLA-
A∗02:01 with spliced epitope candidate KRAS5−6/8−14 G12V,
non-spliced epitope candidate KRAS5−14 G12V, as well as two
control peptides (peptides #1 and #2), in which either the
N-terminal residue or one of the central residues was substituted,
as compared to the epitope candidates (Figures 7A–K). The
crystal structures of these individual HLA-I-peptide complexes
were determined at resolutions ranging from 1.4 to 1.58 Å
by molecular replacement using PDB ID 5ENW as a search
model (Supplementary Table 3). The global superposition of
all these four peptide-HLA-I complexes in the peptide binding
groove reveals a similar binding orientation with a root mean
square deviation value (rmsd) of 0.124 Å. The electron densities
for all four peptides are also well-defined over the entire
peptide length.
Some structural differences in individual peptide binding were
observed when comparing the 9 mer peptides (KRAS5−6/8−14
G12V [KL][VVGAVGV] and peptide #2 KLVVVAVGV) with
the 10 mer peptides (KRAS5−14 G12V [KLVVVGAVGV] and
peptide #1 YLVVVGAVGV). Comparison of peptides with
a same length generally only reveals a single amino acid
change in a similar orientation or the addition of a side
chain, e.g., when V replaces G in peptide #2 as compared
to KRAS5−14 G12V peptide (Figures 7A–D). Specifically, while
the N-terminal and C-terminal ends of all four peptides
match perfectly, structural superposition reveals conformations
in the middle portions of peptide KRAS5−6/8−14 G12V and
peptide #2 unique from the remaining two peptide ligands
(KRAS5−14 G12V and peptide #1). In the latter two cases, the
middle portions of the peptides containing P4, P5, and P6
residues bulge out of the binding pockets to accommodate both
peptide ends inside the peptide-binding groove of the HLA-I
molecule (Figures 7C,D,G,H).
We next evaluated at the detailed interactions between HLA-
A∗02:01 and individual peptides. Throughout these interfaces,
extensive hydrophobic and hydrogen bonding networking is seen
with the majority of peptide residues participating in the contact
with HLA-I residues Y7, F9, M45, E63, K66, V67, H70, T73, T80,
L81, Y84, Y99, Y116, T143, K146, W147, V152, Y159, W167,
Y171 (Figures 7E–H).
In the HLA-I-peptide #1 complex, the N-terminal P1
Y residue makes hydrophobic contact with T163, which
is missing in all the other three peptide complexes and
may explain the significantly higher binding affinity of 10
mer peptide #1 compared to 10 mer KRAS5−14 G12V
peptide (Figure 7H). The A and F pockets forming the
peptide binding groove of HLA-I are mostly composed of
hydrophobic residues and some 12 polar and 21 van der
Waals contacts were, throughout the peptide length in all
complexes, observed between the peptide moiety and HLA-
A∗02:01.
While the HLA-I interaction interface seems to be conserved
in both spliced peptide KRAS5−6/8−14 G12V and non-spliced
peptide KRAS5−14 G12V, the binding affinity of KRAS5−6/8−14
G12V peptide toward HLA-A∗02:01 is higher compared
to the KRAS5−14 G12V peptide (Figure 6C). Hence, to
understand this differential affinity of these peptides for HLA-
A∗02:01, we compared the crystal structures of KRAS5−6/8−14
G12V and KRAS5−14 G12V peptides and modified variants
(peptide #1 and #2) bound to HLA-A∗02:01 complexes in
more detail (Figures 7I–K). The superpositions of either
KRAS5−6/8−14 G12V peptide and peptide #2 or KRAS5−14 G12V
peptide and peptide #1 do not show any relevant differences
(Figures 7I,J).
In contrast, although the structural superposition of
KRAS5−6/8−14 G12V and KRAS5−14 G12V peptides bound
to HLA-A∗02:01 molecules reveals a similar type of HLA-I
interaction network at their N-terminal and C-terminal regions,
their structural arrangements deviate in their middle portions.
Due to this, the spliced peptide KRAS5−6/8−14 G12V makes
several unique interactions with HLA-A∗02:01. Firstly, in the
structure of HLA-A∗02:01 complexed with spliced peptide
KRAS5−6/8−14 G12V, the P6 A residue makes both hydrogen
bonding and van der Waals contacts with the side chain of
T73 residue of HLA-I, whereas the P6G residue of KRAS5−14
G12V is not in contact with HLA-A∗02:01 and its P7A residue
maintains only hydrophobic interactions with T73.
Another difference between both these complexes is at their
C-termini. In the HLA-I-KRAS5−14 G12V peptide complex, the
HLA-A∗02:01 K146 residue adopts a different orientation, due
to which it interacts with only the terminal P residue. In
the HLA-I-KRAS5−6/8−14 G12V complex, the amino group of
K146 forms a hydrogen bond with both the carbonyl oxygen
of the P-1 residue and the terminal P residue. Furthermore,
though KRAS5−14 G12V is longer [10 amino acids, compared to
KRAS5−6/8−14 G12V (9 amino acids)] and reorganizes its central
region in the HLA binding groove, this structural rearrangement
does not favor any additional contacts with HLA-A∗02:01.
From our structural analysis, we can predict that the higher
affinity of the spliced KRAS5−6/8−14 G12V peptide, compared to
KRAS5−14 G12V peptide, might be due to these two additional
hydrogen bonding contacts between the spliced peptides P6A
residue and the T73 of HLA-A∗02:01, as well as the spliced
peptides P-1 residue and the K146 residue of the HLA-A∗02:01
molecule (Figure 7K).
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FIGURE 7 | HLA-A*02:01-KRAS G12V peptides binding mode. Binding mode of spliced epitope candidate KRAS5−6/8−14 G12V [KL][VVGAVGV], non-spliced epitope
candidate KRAS5−14 G12V [KLVVVGAVGV], peptides #1 YLVVVGAVGV and #2 KLVVVAVGV to HLA-A*02:01 complex. (A–D) 2Fo-Fc electron density map contoured
at 1σ for KRAS5−6/8−14 G12V peptide (A), peptide #2 (B), non-spliced peptide KRAS5−14 G12V (C), and peptide #1 (D). (E–H) Binding of spliced peptide
(Continued)
Frontiers in Immunology | www.frontiersin.org 12 November 2019 | Volume 10 | Article 2572
Mishto et al. Pipeline Identifying Spliced Neoepitope Candidates
FIGURE 7 | KRAS5−6/8−14 G12V (E; green sticks), peptide #2 (F; yellow sticks), non-spliced peptide KRAS5−14 G12V (G; brown sticks), and peptide #1 (H; cyan
sticks) to HLA-A*02:01 protein (gray molecular surface). (I–K) Overlay of KRAS5−6/8−14 G12V and peptide #2 binding to HLA-A*02:01 (I), KRAS5−14 G12V peptide
and peptide #1 (J), as well as KRAS5−6/8−14 G12V and KRAS5−14 G12V peptides (K) binding to HLA-A*02:01 molecule. All peptides are shown as sticks and in
(A–D), peptide residues are labeled with one-letter amino acid codes. In (E–K), the residues of HLA-A*02:01 that are extended in the peptide binding interface are
labeled with single-letter amino acid codes. In (B,F,I), * indicates the alternate conformations for residues V4 and V5 of peptide #2. In (C,G,J–K), *indicates the
alternate conformations for residues V3 of KRAS5−14 G12V peptide.
Potential Recognition of KRAS5–6/8–14 G12V
and KRAS5−14 G12V Epitope Candidates
Within HLA-A∗02:01 Cleft by Different TCRs
Once the peptide binds to a HLA-I molecule, it gets displayed
for TCR recognition, which can then induce effective immune
responses. Using structure as a tool, we tried to determine
the mode of TCR-HLA-I-peptide interaction. Our evaluation
of HLA-I-KRAS5−6/8−14 G12V and HLA-I-KRAS5−14 G12V
peptide complexes provides a link to the potential cross
recognition by a given CD8+ T cell clone. The middle portion
of both spliced and non-spliced epitope candidates containing
P4 and P5 residues does not make ample contacts with the
HLA-A∗02:01 molecule but has limited flexibility in the crystal
structure, otherwise this would not have been solved in the
structure (Figures 8A,B). In the HLA-A∗02:01-KRAS5−14 G12V
peptide complex, the middle portion that bulges out from the
binding groove makes it more accessible for TCR recognition
(Figure 8B). The side chain of P4V and P5V residues are facing
in an upward direction and can be easily accommodated into the
binding pocket located over the central peptide, formed by the
most structurally diverse CDR loops, CDR3α and CDR3β of the
TCR. Similarly, in the HLA-I-KRAS5−6/8−14 G12V complex, the
side chain of the P4V residue is available to mediate hydrophobic
contact for TCR recognition. Also, in both complexes there
is a possibility of hydrogen bonding interactions between the
main chain carbonyl and amide groups of P4 and P5 residues
with the TCR (Figures 8A–C). Hence, our analysis of the crystal
structure suggests that both the spliced KRAS5−6/8−14 G12V
and the non-spliced KRAS5−14 G12V epitope candidates can be
contacted by the same TCR at their P4 site, thereby promoting
cross reactivity.
On the other hand, even though some potential TCR
cross reactivity exists toward both spliced and non-spliced
epitope candidates, the structural superposition of both peptide
complexes revealed deviation in their peptide conformation at
the region where the TCR interaction is expected to happen
(Figure 8C). Hence, depending on the direction that the TCR
encounters in the HLA-I-peptide complex, there might be
a definite possibility of having TCRs that exhibit preference
or exclusive binding toward either the non-spliced or the
spliced epitope, rather than recognizing both of them. As the
KRAS5−6/8−14 G12V possess three peptide residues, P4V, P5V,
and P6G, that can mediate both hydrogen bonding and van der
Waals contacts with a TCR, whilst the spliced peptide contains
only P4V and P5G residues; hence, we can speculate that TCRs
more likely will have selectivity and specificity for one of the two
epitope candidates.
DISCUSSION
Epitope discovery is an essential first step for antigen-
targeted immunotherapies against cancer, infection and some
autoimmune diseases. In the last decade, several studies proposed
strategies to achieve this, especially in light of anti-cancer
immunotherapies. The majority of these studies identify epitope
candidates in HLA-I immunopeptidomes eluted from cells.
Although this strategy guarantees that the identified epitope is
presented at the cell surface, it cannot include all targetable
epitopes because of its relative low sensitivity (51). TCRs can still
be considered more sensitive than MS-based methods and can
sense even a few epitope molecules bound to HLA-I molecules
to trigger cytotoxic responses. There are several examples of
epitopes that were not identified by analytical methods based
on HLA-I immunopeptidomes of cells, but were well-recognized
by specific CTLs. The pipeline that we proposed here tries to
circumvent this problem. While starting from a large number
of theoretical epitope candidates, the pipeline narrows them
down to a few selected candidates step by step. One of the
advantages of our strategy is that its sequential steps could
be exchanged and adapted to the specific requirements of a
given application. For instance, in this study we developed a
model to rank antigens by their potential over-representation
in HLA-I immunopeptidomes considering four protein features,
without including any cell-specific assays, such as transcriptome
or intracellular proteome analysis. If such data was available,
our pipeline could use more complex algorithms, such as that
published by Pearson et al. (37), and likely reach a more in-depth
antigen selection.
The same principle of flexible structure and interchangeable
steps could be applied to the “in vitro selection” section of our
pipeline. In this study, we tested in vitro three steps of the HLA-I
APP pathway: proteasome-mediated generation; TAP-mediated
transport into the ER lumen; and the efficient binding to the
selected HLA-I variant. While some epitopes may be presented
by HLA-I molecules in a proteasome- and TAP-independent
fashion, the majority of HLA-I-restricted epitopes depends on
these two steps.
Efficient binding to the selected HLA-I molecule is, on the
contrary, mandatory. However, although a threshold of 500 nM
would capture ∼85% of all HLA-I-bound peptides (52, 53), it
is still an open question what the optimal IC50 threshold is to
define a “good epitope target” for ATT. The most determining
factor could be the off-rate of peptide binding, a feature that
we likely determine indirectly via IC50, because poor and good
peptides have been reported to have similar on-rates but different
off-rates (54).
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FIGURE 8 | Potential recognition of KRAS5−6/8−14 G12V and KRAS5−14 G12V epitope candidates within HLA-A*02:01 cleft by different TCRs. (A,B) Side view of
binding mode of spliced epitope candidate KRAS5−6/8−14 G12V [KL][VVGAVGV] (A; green sticks), non-spliced epitope candidate KRAS5−14 G12V [KLVVVGAVGV] (B;
brown sticks) into the HLA-A*02:01 binding grove displaying the peptide residues exposed for TCR recognition. (C) Structural superposition of KRAS5−6/8−14 G12V
and KRAS5−14 G12V peptides complexed with HLA-A*02:01 molecule revealing the conformational deviation at their middle region where TCR interaction is expected
to happen. In all three panels, the HLA-A*02:01 protein is shown as gray molecular surface and peptide residues as sticks. In (A,B), peptide residues exposed for TCR
recognition are labeled. In all panels, some of the residues of HLA-A*02:01 that are extended in the peptide binding interface are labeled.
Of course, the “in vitro selection” section of our pipeline could
enlist other APP steps such as tapasin-dependency, cytosolic
peptidase and ERAP trimming, etc. (2, 55), which could be
selectively chosen based on tumor features and the known APP
pathway of the target antigen.
Our pipeline identifies epitope candidates which shall further
be validated by isolating specific CTL clones and their TCRs and
using them to confirm that the epitope candidates are produced
in cellulo and eventually in vivo. There are several strategies
to this end. For example, the KRAS5−6/8−14 spliced epitope
candidate here identified has been validated in collaboration
with Blankenstein et al. (56). Specific TCRs have been isolated
from humanized ABabDII mice (57), cloned into expressing
vectors and transduced into human PBMCs. Transduced human
CD8+ T cells selectively recognized the KRAS5−6/8−14 spliced
epitope. They also recognized human cancer cell lines expressing
KRAS G12V antigen and HLA-A∗02:01 complex and release
IFNγ. They do not recognize a cancer cell line expressing the
wild type KRAS G12 protein and the HLA-A∗02:01 complex.
These outcomes validated the KRAS5−6/8−14 spliced epitope
candidate as a genuine epitope (56). We tried to identify
the KRAS5−6/8−14 G12V spliced and the KRAS5−14 G12V
non-spliced epitope candidates through the MS measurement
of the HLA-I immunopeptidomes of the SW480 pancreatic
adenocarcinoma cell line, which expresses the HLA-A∗02:01
complex and the KRAS G12V mutated protein (42). Despite
CTL clones could recognize both epitope candidates presented
by cancer cell lines (42, 56), none of the two peptides was
identified in the SW480-derived HLA-I immunopeptidomes
(data not shown), thereby confirming the usefulness of the
pipeline described here.
Another advantage of our pipeline is its ability to select
and identify proteasome-generated spliced epitope candidates,
which we and other groups have found to represent a sizeable
pool of immunologically relevant epitopes, especially within
the framework of anti-cancer immunotherapies (3, 11, 12,
20, 21, 44, 58). The PCPS reaction was shown to generate
a large number and a significant amount of spliced peptides
in the in vitro processing of KRAS2−35 neoantigen by 20S
proteasomes. This suggests that we might have previously
underestimated PCPS frequency in the in vitro proteasome
digestions, likely due to the low MS sensitivity available at that
time (23).
The benefit of including these unconventional epitopes in
our pipeline is evident. The recurrent KRAS G12V mutation
can be efficiently presented by HLA-A∗02:01 complexes only
through spliced peptides. TCRs specific to this spliced epitope
candidate could be used to treat around 15–20% of colorectal
cancer and pancreatic adenocarcinoma by ATT. According to
our analysis, the G12V mutation promotes not only the binding
affinity of the KRAS5−6/8−14 G12V spliced epitope candidate
to HLA-A∗02:01 complex, but also the splicing reaction at
that site, since we did not identify the KRAS5−6/8−14 G12
spliced peptide in the in vitro digestion of wild type KRAS2−35
Frontiers in Immunology | www.frontiersin.org 14 November 2019 | Volume 10 | Article 2572
Mishto et al. Pipeline Identifying Spliced Neoepitope Candidates
G12 by 20S proteasomes. The KRAS5−6/8−14 G12V sequence
[KL][VVGAVGV] cannot be generated by any other human
protein by peptide hydrolysis or cis peptide splicing (data
not shown), thereby defining it as a unique neoepitope. In
the KRAS2−35 G12V polypeptide digestion, we also identified
the non-spliced epitope candidate KRAS5−14 G12V, which was
shown to be recognized by PBMCs of pancreatic adenocarcinoma
patients (42). For a cancer-targeted strategy, it would be
informative to perform in vitro digestions using proteasome
isoforms recapitulating those present in the target cancer,
since they vary from tumor to tumor with implications for
the quantity (and perhaps the quality) of peptide produced
(4, 5, 27). Both KRAS5−6/8−14 G12V and KRAS5−14 G12V
epitope candidates are efficiently transported by TAP into
the ER lumen, which is then no bottleneck. The non-spliced
epitope candidate, however, binds HLA-A∗02:01 less efficiently
than the spliced epitope candidate with an IC50 larger than
300 nM, which could be higher than the binding affinity
currently suggested for immunodominant epitopes. According
to analysis of the HLA-A∗02:01-peptide crystal structures, the
two epitope candidates differ in the region exposed to TCRs.
Therefore, we would expect that unique CD8+ T cell clones
could recognize these, although cross-reactive TCRs cannot be
excluded. In the case of cross-reactivity, the immunodominance
of the spliced epitope over the non-spliced epitope might
be favored by the higher binding affinity to HLA-A∗02:01
complex. We do not have enough information about the
other steps of their APP pathways, including production
by cancer-associated proteasome isoforms, to conclude about
presentation in cancer patients. Yet, our pipeline allows
identification of potential new neoepitopes derived from peptide
splicing that are unique for a driver in oncogenesis, KRAS G12V.
Such epitopes could be critical in new vaccination approaches for
the related tumors.
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